Literature DB >> 15949847

Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis.

R Schulz1, T Rassaf, P B Massion, M Kelm, J-L Balligand.   

Abstract

Nitric oxide synthases (NOS) are the enzymes responsible for nitric oxide (NO) generation. To date, 3 distinct NOS isoforms have been identified: neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3). Biochemically, NOS consists of a flavin-containing reductase domain, a heme-containing oxygenase domain, and regulatory sites. NOS catalyse an overall 5-electron oxidation of one Nomega-atom of the guanidino group of L-arginine to form NO and L-citrulline. NO exerts a plethora of biological effects in the cardiovascular system. The basal formation of NO in mitochondria by a mitochondrial NOS seems to be one of the main regulators of cellular respiration, mitochondrial transmembrane potential, and transmembrane proton gradient. This review focuses on recent advances in the understanding of the role of enzyme and enzyme-independent NO formation, regulation of NO bioactivity, new aspects of NO on cardiac function and morphology, and the clinical impact and perspectives of these recent advances in our knowledge on NO-related pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949847     DOI: 10.1016/j.pharmthera.2005.04.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  40 in total

Review 1.  Interference with the renin-angiotensin system in heart failure.

Authors:  R Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02       Impact factor: 3.000

Review 2.  The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.

Authors:  N van Leeuwen; J J Swen; H-J Guchelaar; L M 't Hart
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

3.  Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers.

Authors:  M L Becker; L E Visser; C Newton-Cheh; J C M Witteman; A Hofman; A G Uitterlinden; B H Ch Stricker
Journal:  Diabetologia       Date:  2008-09-03       Impact factor: 10.122

4.  Characterization of potential S-nitrosylation sites in the myocardium.

Authors:  Mark J Kohr; Angel M Aponte; Junhui Sun; Guanghui Wang; Elizabeth Murphy; Marjan Gucek; Charles Steenbergen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-28       Impact factor: 4.733

5.  Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.

Authors:  Saumya Ramanathan; Stacy Mazzalupo; Scott Boitano; William R Montfort
Journal:  Biochemistry       Date:  2011-08-16       Impact factor: 3.162

Review 6.  Nitric oxide release: part III. Measurement and reporting.

Authors:  Peter N Coneski; Mark H Schoenfisch
Journal:  Chem Soc Rev       Date:  2012-02-24       Impact factor: 54.564

Review 7.  Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones.

Authors:  Jawwad Yusuf; M Usman Khan; Yaser Cheema; Syamal K Bhattacharya; Karl T Weber
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

8.  A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers.

Authors:  Matthijs L Becker; Loes E Visser; Christopher Newton-Cheh; Albert Hofman; André G Uitterlinden; Jacqueline C M Witteman; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  Regulation of FMN subdomain interactions and function in neuronal nitric oxide synthase.

Authors:  Robielyn P Ilagan; Jesús Tejero; Kulwant S Aulak; Sougata Sinha Ray; Craig Hemann; Zhi-Qiang Wang; Mahinda Gangoda; Jay L Zweier; Dennis J Stuehr
Journal:  Biochemistry       Date:  2009-05-12       Impact factor: 3.162

Review 10.  Bench-to-bedside review: nitric oxide in critical illness--update 2008.

Authors:  Steven M Hollenberg; Ismail Cinel
Journal:  Crit Care       Date:  2009-07-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.